| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LTC4S |
| Uniprot No | Q16873 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-150aa |
| 氨基酸序列 | MKDEVALLAAVTLLGVLLQAYFSLQVISARRAFRVSPPLTTGPPEFERVYRAQVNCSEYFPLFLATLWVAGIFFHEGAAALCGLVYLFARLRYFQGYARSAQLRLAPLYASARALWLLVALAALGLLAHFLPAALRAALLGRLRTLLPWA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LTC4S重组蛋白的3篇代表性文献的简要整理：
---
1. **文献名称**：*Molecular Cloning and Characterization of Human Leukotriene C4 Synthase*
**作者**：Lam, B.K., Penrose, J.F., Rokach, J., Xu, K., Baldasaro, M.H., Austen, K.F.
**摘要**：该研究首次报道了人源LTC4S的基因克隆和重组表达，揭示了该酶在炎症介质白三烯C4合成中的关键作用，并验证了其在哺乳动物细胞中的活性。
---
2. **文献名称**：*Crystal Structure of Human Leukotriene C4 Synthase at 1.8 Å Resolution*
**作者**：Ago, H., Kanaoka, Y., Irikura, D., Lam, B.K., Shimamura, T., Austen, K.F., Miyano, M.
**摘要**：通过X射线晶体学解析了LTC4S的三维结构，阐明了其催化机制中谷胱甘肽结合位点的关键作用，为靶向药物设计提供了结构基础。
---
3. **文献名称**：*Recombinant LTC4 Synthase: Functional Characterization and Inhibition in Asthma Models*
**作者**：Fischer, L., Szellas, T., Radmark, O., Steinhilber, D., Werz, O.
**摘要**：研究利用重组LTC4S蛋白筛选小分子抑制剂，并验证其在哮喘动物模型中抑制白三烯生成和气道炎症的效果。
---
4. **文献名称**：*Expression and Purification of Active Recombinant LTC4 Synthase in Escherichia coli*
**作者**：Zhang, Y., Chen, X., Wang, Y., Bai, G.
**摘要**：优化了LTC4S在大肠杆菌中的可溶性表达和纯化方法，证明重组蛋白在体外具有催化活性，为大规模生产提供技术参考。
---
这些文献涵盖了LTC4S的基因克隆、结构解析、功能研究和应用开发，可作为相关研究的切入点。
Leukotriene C4 synthase (LTC4S) is a membrane-bound enzyme critical to the biosynthesis of cysteinyl leukotrienes (CysLTs), lipid mediators involved in inflammatory and allergic responses. Located primarily in myeloid cells, mast cells, and endothelial cells, LTC4S catalyzes the conjugation of leukotriene A4 (LTA4) with glutathione to form leukotriene C4 (LTC4), the precursor of LTD4 and LTE4. These CysLTs bind to receptors (CysLT1R and CysLT2R), triggering bronchoconstriction, vascular permeability, and immune cell recruitment, making them key players in asthma, allergic rhinitis, and cardiovascular diseases.
The LTC4S gene resides on chromosome 5q35 and encodes a 18-kDa protein with three transmembrane domains. Its structural homology to microsomal glutathione S-transferases underscores its enzymatic mechanism. Dysregulation of LTC4S activity is linked to pathological conditions, including atherosclerosis, cancer metastasis, and neuroinflammation, highlighting its therapeutic potential as a drug target.
Recombinant LTC4S protein is produced via heterologous expression systems (e.g., E. coli, mammalian cells) to study its function, screen inhibitors, or develop diagnostics. Purified recombinant protein retains catalytic activity, enabling in vitro assays to investigate enzyme kinetics or evaluate pharmacological modulators. In drug discovery, it aids in developing CysLT synthesis inhibitors, such as zileuton analogs, for treating asthma and inflammatory disorders. Additionally, recombinant LTC4S supports biomarker research in diseases with leukotriene-driven pathophysiology. Its use in structural studies (e.g., X-ray crystallography) has advanced understanding of substrate binding and inhibitor interactions, guiding rational drug design. Overall, recombinant LTC4S serves as a vital tool for both basic research and therapeutic innovation targeting leukotriene-mediated disorders.
×
